NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

SELLAS Life Sciences Group logo
$13.66 -1.20 (-8.08%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$14.27 +0.61 (+4.47%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About SELLAS Life Sciences Group Stock (NASDAQ:SLS)

Advanced

Key Stats

Today's Range
$13.39
▼
$15.19
50-Day Range
$7.47
▼
$19.15
52-Week Range
$1.39
▼
$24.89
Volume
15.36 million shs
Average Volume
7.65 million shs
Market Capitalization
$2.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development.

Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer. SELLAS has also been developing SLS009, a small-molecule CDK9 inhibitor being studied for blood cancers, including acute myeloid leukemia.

SELLAS is headquartered in New York. Its chief executive officer is Angelos Stergiou, who also serves as the company’s chairman.

AI Generated. May Contain Errors.

SELLAS Life Sciences Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

SLS MarketRank™: 
0.643165067445 of 5 stars

SELLAS Life Sciences Group scored higher than 13% of companies evaluated by MarketBeat, and ranked 819th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SELLAS Life Sciences Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Downside Risk

    SELLAS Life Sciences Group has a consensus price target of $10.00, representing about 26.8% downside from its current price of $13.66.

  • Amount of Analyst Coverage

    SELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.

  • Read more about SELLAS Life Sciences Group's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SELLAS Life Sciences Group is -68.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SELLAS Life Sciences Group is -68.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SELLAS Life Sciences Group has a P/B Ratio of 21.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    28.66% of the float of SELLAS Life Sciences Group has been sold short.
  • Short Interest Ratio / Days to Cover

    SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in SELLAS Life Sciences Group has recently increased by 6.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    SELLAS Life Sciences Group does not currently pay a dividend.

  • Dividend Growth

    SELLAS Life Sciences Group does not have a long track record of dividend growth.

  • News Sentiment

    SELLAS Life Sciences Group has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 54 news articles for SELLAS Life Sciences Group this week, compared to 5 articles on an average week.
  • Search Interest

    36 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    14 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SELLAS Life Sciences Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $206,454.00 in company stock.

  • Percentage Held by Insiders

    1.30% of the stock of SELLAS Life Sciences Group is held by insiders.

  • Percentage Held by Institutions

    17.38% of the stock of SELLAS Life Sciences Group is held by institutions.

  • Read more about SELLAS Life Sciences Group's insider trading history.
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLS Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Sellas Life Sciences Shares Sink After Pricing Public Offering
See More Headlines

SLS Stock Analysis - Frequently Asked Questions

SELLAS Life Sciences Group's stock was trading at $3.77 at the beginning of 2026. Since then, SLS shares have increased by 262.3% and is now trading at $13.66.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its earnings results on Thursday, November, 12th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05).

SELLAS Life Sciences Group's stock reverse split on the morning of Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

SELLAS Life Sciences Group's top institutional investors include State Street Corp (5.14%), Dagco Inc. (0.66%), Goldman Sachs Group Inc. (0.54%) and Marshall Wace LLP (0.14%). Insiders that own company stock include John Thomas Burns, Dragan Cicic, Katherine Bach Kalin, Jane Wasman and Nostrand Robert L Van.
View institutional ownership trends
.

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include NVIDIA (NVDA), Novavax (NVAX), Advanced Micro Devices (AMD), Ford Motor (F), Tesla (tsla), Inovio Pharmaceuticals (INO) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/12/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SLS
CIK
1390478
Employees
13
Year Founded
2006

Price Target and Rating

High Price Target
$10.00
Low Price Target
$10.00
Potential Upside/Downside
-26.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.95%
Return on Assets
-29.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.92
Quick Ratio
14.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.65 per share
Price / Book
21.02

Miscellaneous

Outstanding Shares
203,860,000
Free Float
201,209,000
Market Cap
$2.78 billion
Optionable
Optionable
Beta
2.73

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:SLS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners